Zobrazeno 1 - 10
of 96
pro vyhledávání: '"JOSEPHINE Harrington"'
Autor:
Anthony E. Peters, Robert M. Clare, Karen Chiswell, Josephine Harrington, Anita Kelsey, Adrian Hernandez, Gary Michael Felker, Robert J. Mentz, Adam D. DeVore
Publikováno v:
ESC Heart Failure, Vol 11, Iss 5, Pp 2813-2824 (2024)
Abstract Aims Clinical trials in heart failure with mildly reduced or preserved ejection fraction (HFmrEF/HFpEF) commonly have detailed eligibility criteria. This may contribute to challenges with efficient enrolment and questions regarding the gener
Externí odkaz:
https://doaj.org/article/5c8c85d22678438092bc35a30f298625
Autor:
Josephine Harrington, Anne S. Hellkamp, Kenneth W. Mahaffey, Günter Breithardt, Jonathan L. Halperin, Graeme J. Hankey, Richard C. Becker, Christopher C. Nessel, Scott D. Berkowitz, Keith A. A. Fox, Daniel E. Singer, Shaun G. Goodman, Manesh R. Patel, Jonathan P. Piccini
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 13, Iss 11 (2024)
Background Days alive out of hospital (DAOH) is an objective and patient‐centered net benefit end point. There are no assessments of DAOH in clinical trials of interventions for atrial fibrillation (AF), and it is not known whether this end point i
Externí odkaz:
https://doaj.org/article/a5fb44f1354d4d29a8e3aab8c544798b
Autor:
Josephine Harrington, Jie‐Lena Sun, Gregg C. Fonarow, Stephen B. Heitner, Punag H. Divanji, Gary Binder, Larry A. Allen, Brooke Alhanti, Clyde W. Yancy, Nancy M. Albert, Adam D. DeVore, G. Michael Felker, Stephen J. Greene
Publikováno v:
Journal of the American Heart Association: Cardiovascular and Cerebrovascular Disease, Vol 12, Iss 10 (2023)
Background Many patients with heart failure (HF) have severely reduced ejection fraction but do not meet threshold for consideration of advanced therapies (ie, stage D HF). The clinical profile and health care costs associated with these patients in
Externí odkaz:
https://doaj.org/article/1562516935a04e21a697a6a639dfaab1
Autor:
Josephine Harrington, Gregg C. Fonarow, Muhammad Shahzeb Khan, Adrian Hernandez, Stefan Anker, Michael Böhm, Stephen J. Greene, G. Michael Felker, Muthiah Vaduganathan, Javed Butler
Publikováno v:
JACC Heart Fail
BACKGROUND: Initiation and up-titration of guideline-directed medical therapies (GDMT) for heart failure with reduced ejection fraction (HFrEF) remains suboptimal, in part due to concerns regarding tolerability and adverse events (AE). OBJECTIVES: To
Autor:
Josephine Harrington, Jonathan P. Piccini, John H. Alexander, Christopher B. Granger, Manesh R. Patel
Publikováno v:
Journal of the American College of Cardiology. 81:771-779
Autor:
Josephine Harrington, Robert J Mentz
Publikováno v:
European Journal of Heart Failure.
Autor:
Nijat Aliyev, Muhammad Usman Almani, Muhammad Qudrat-Ullah, Josephine Harrington, Gregg C. Fonarow, Javed Butler, Ambarish Pandey, Muhammad Shahzeb Khan, Stephen J. Greene
Publikováno v:
JACC: Heart Failure. 11:121-123
Autor:
Josephine, Harrington, W Schuyler, Jones, Jacob A, Udell, Karen, Hannan, Deepak L, Bhatt, Stefan D, Anker, Mark C, Petrie, Ola, Vedin, Javed, Butler, Adrian F, Hernandez
Publikováno v:
JACC: Heart Failure. 10:404-414
Acute coronary syndrome (ACS) is frequently complicated by evidence of heart failure (HF). Those at highest risk for acute decompensated HF in the setting of ACS (ACS-HF) are older, female, and have preexisting heart disease, type 2 diabetes mellitus
Autor:
Jacob A. Udell, W. Schuyler Jones, Mark C. Petrie, Josephine Harrington, Stefan D. Anker, Deepak L. Bhatt, Adrian F. Hernandez, Javed Butler
Publikováno v:
Journal of the American College of Cardiology. 79:2058-2068
Autor:
Josephine Harrington, Anthony P. Carnicelli, Kaiyuan Hua, Lars Wallentin, Manesh R. Patel, Stefan H. Hohnloser, Robert P. Giugliano, Keith A.A. Fox, Ziad Hijazi, Renato D. Lopes, Sean D. Pokorney, Hwanhee Hong, Christopher B. Granger
Publikováno v:
Circulation.
BACKGROUND: There is uncertainty surrounding the use of direct oral anticoagulants (DOACs) in patients with kidney dysfunction. METHODS: Using the COMBINE AF (A Collaboration Between Multiple Institutions to Better Investigate Non-Vitamin K Antagonis